Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

Summary

This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.

Conditions

• Acute Ischemic Stroke
• Atrial Fibrillation

Interventions

OTHER

Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)

Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.

OTHER

Usual care for atrial fibrillation

Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.

Sponsors & Collaborators

• University Heart & Vascular Center Hamburg, Department of Cardiology

  collaborator UNKNOWN

• Department of Neurology, Royal Melbourne Hospital

  collaborator UNKNOWN

• Melbourne Heart Centre, Royal Melbourne Hospital

  collaborator UNKNOWN

• Hotchkiss Brain Institute, University of Calgary

  collaborator OTHER

• Department of Neurology and Neurosurgery, Brain Center, University Medical Center Utrecht

  collaborator UNKNOWN

• UMC Utrecht

  collaborator OTHER

• Edinburgh Clinical Trials Unit, Cerebrovascular Research Group, Centre for Clinical Brain Sciences, University of Edinburgh

  collaborator UNKNOWN

• Department of Cardiovascular Sciences, University of Leicester British Heart Foundation Cardiovascular Research Centre

  collaborator UNKNOWN

• CTC-NORTH

  collaborator UNKNOWN

• Stroke Alliance for Europe (SAFE)

  collaborator UNKNOWN

• Kompetenznetz Vorhofflimmern e.V. (AFNET)

  collaborator UNKNOWN

• Universitätsklinikum Hamburg-Eppendorf

  lead OTHER

Principal Investigators

• Götz Thomalla, MD · Universitätsklinikum Hamburg-Eppendorf

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-11-06

Primary Completion

2031-07-31

Completion

2031-09-30

Countries

• Germany

Study Locations